Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Dec;174(12):1947-54.
doi: 10.1001/jamainternmed.2014.5302.

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial

David A Fiellin  1 , Richard S Schottenfeld  2 , Christopher J Cutter  1 , Brent A Moore  2 , Declan T Barry  2 , Patrick G O'Connor  1
Affiliations
Randomized Controlled Trial

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial

David A Fiellin et al. JAMA Intern Med. 2014 Dec.

Abstract

Importance: Prescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy.

Objective: To determine the efficacy of buprenorphine taper vs ongoing maintenance therapy in primary care-based treatment for prescription opioid dependence.

Design, setting, and participants: We conducted a 14-week randomized clinical trial that enrolled 113 patients with prescription opioid dependence from February 17, 2009, through February 1, 2013, in a single primary care site.

Interventions: Patients were randomized to buprenorphine taper (taper condition) or ongoing buprenorphine maintenance therapy (maintenance condition). The buprenorphine taper was initiated after 6 weeks of stabilization, lasted for 3 weeks, and included medications for opioid withdrawal, after which patients were offered naltrexone treatment. The maintenance group received ongoing buprenorphine therapy. All patients received physician and nurse support and drug counseling.

Main outcomes and measures: Illicit opioid use via results of urinanalysis and patient report, treatment retention, and reinitiation of buprenorphine therapy (taper group only).

Results: During the trial, the mean percentage of urine samples negative for opioids was lower for patients in the taper group (35.2% [95% CI, 26.2%-44.2%]) compared with those in the maintenance group (53.2% [95% CI, 44.3%-62.0%]). Patients in the taper group reported more days per week of illicit opioid use than those in the maintenance group once they were no longer receiving buprenorphine (mean use, 1.27 [95% CI, 0.60-1.94] vs 0.47 [95% CI, 0.19-0.74] days). Patients in the taper group had fewer maximum consecutive weeks of opioid abstinence compared with those in the maintenance group (mean abstinence, 2.70 [95% CI, 1.72-3.75] vs 5.20 [95% CI, 4.16-6.20] weeks). Patients in the taper group were less likely to complete the trial (6 of 57 [11%] vs 37 of 56 [66%]; P < .001). Sixteen patients in the taper group reinitiated buprenorphine treatment after the taper owing to relapse.

Conclusions and relevance: Tapering is less efficacious than ongoing maintenance treatment in patients with prescription opioid dependence who receive buprenorphine therapy in primary care.

Trial registration: clinicaltrials.gov Identifier: NCT00555425.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Fiellin has received honoraria for serving on expert advisory boards to monitor for diversion, misuse, and abuse of buprenorphine for Pinney Associates and ParagonRx and has received honoraria from the American Society of Addiction Medicine to serve as the medical director of the Physician Clinical Support Systems for Buprenorphine and Primary Care and from the American Academy of Addiction Psychiatry to serve as a consultant to the Physician Clinical Support Systems for Buprenorphine and Opioids. Drs Schottenfeld and Moore received support from the Connecticut Mental Health Center, State of Connecticut. Dr Barry has received compensation for expert testimony addressing addiction and pain. No other disclosures were reported.

Figures

Figure 1.
Figure 1.
CONSORT Flowchart of Enrollment, Treatment, and Follow-up
Figure 2.
Figure 2.. Treatment Retention and Mean Buprenorphine Dosage for Patients With Prescription Opioid Dependence
Patients were assigned to the taper or the maintenance condition. Buprenorphine treatment was administered as a tablet formulation of buprenorphine hydrochloride and naloxone hydrochloride in a 4:1 ratio.
See this image and copyright information in PMC

References

    1. Substance Abuse and Mental Health Services Administration. Results From the 2012 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
    1. CDC grand rounds: prescription drug overdoses–a US epidemic. Morb Mortal Wkly Rep. 2012;61(1):10–13. - PubMed
    1. Kirschner N, Ginsburg J, Sulmasy LS; Health and Public Policy Committee of the American College of Physicians. Prescription drug abuse: a policy position paper from the American College of Physicians. Ann Intern Med. 2014;160(3):198. doi:10.7326/M13-2209. - DOI - PubMed
    1. Center for Substance Abuse Research. Buprenorphine treatment of opioid dependence. CESAR Fax. 2011;20(34). http://www.cesar.umd.edu/cesar/pubs/BuprenorphineCESARFAX.pdf. Accessed September 4, 2014.
    1. Greene P Outpatient drug utilization trends for buprenorphine years 2002–2009. May 10, 2010. http://buprenorphine.samhsa.gov/bwns/2010_presentations_pdf/09_Greene_50.... Accessed September 4, 2014.

Publication types

Associated data